Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The legal team said the jury's decision could make medics think twice before allowing the injured to return to the field.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.
Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’
After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.
FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years
Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial
Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children
1.
Study: Discovery of cellular identity may influence cancer treatment
2.
What is Mohs micrographic surgery? 8 FAQs about Mohs
3.
Breast cancer screening in women's 40s can save lives, study says
4.
For Localized Prostate Cancer, HIFU Is Not Worse Than Prostatectomy.
5.
Scientists Employ Technology to Identify Plagiarism and Forgeries in Published Studies.
1.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
2.
The Cutting-Edge of Phlebectomy: Redefining Vein Care
3.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
4.
Debunking Myths About Systemic Mastocytosis: Separating Fact from Fiction
5.
Understanding Mantle Cell Lymphoma Prognosis.
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
5.
Thromboprophylaxis In Medical Settings
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge